Survodutide.
Survodutide (BI 456906) is an investigational once-weekly injectable peptide that activates two gut-hormone receptors at once: the glucagon receptor (GCGR) and the glucagon-like peptide-1 receptor (GLP-1R).
Survodutide (BI 456906) is an investigational once-weekly injectable peptide that activates two gut-hormone receptors at once: the glucagon receptor (GCGR) and the glucagon-like peptide-1 receptor (GLP-1R). Survodutide is in human trials, and PepCue grades its published evidence B tier (70/100). Also known as BI 456906. This is a research reference, not medical or dosing advice.
What it is
Survodutide (BI 456906) is an investigational once-weekly injectable peptide that activates two gut-hormone receptors at once: the glucagon receptor (GCGR) and the glucagon-like peptide-1 receptor (GLP-1R). It is being co-developed by Boehringer Ingelheim and Zealand Pharma as a candidate treatment for obesity and for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH). It is not an approved medicine and is available only within regulated clinical trials. The dual-receptor design is intended to combine appetite and blood-sugar effects with an added push on energy expenditure and liver-fat handling.
How it works
As a GLP-1 receptor agonist, survodutide slows gastric emptying, enhances glucose-dependent insulin secretion, and reduces appetite through central pathways. Its distinguishing feature is simultaneous agonism of the glucagon receptor, which in this metabolic context is thought to raise energy expenditure and promote hepatic fat mobilization. This balanced dual agonism aims to produce greater weight loss and liver benefit than GLP-1 activation alone. The molecule is engineered for a long half-life to permit weekly subcutaneous dosing.
Mechanism pathways
Activating the GLP-1 receptor to enhance insulin release, slow gastric emptying, and reduce appetite.
Glucagon-like peptide-1 is an incretin hormone released from the gut after a meal. Its receptor is a class B G-protein-coupled receptor found on pancreatic beta cells, on stomach and gut tissue, and on neurons in the hypothalamus and brainstem, including the area postrema. When the receptor is activated, three things happen at once. Beta cells become more responsive to glucose, so insulin secretion rises mainly when blood glucose is already elevated rather than continuously, which is why this class carries a lower intrinsic hypoglycaemia risk than insulin itself. The stomach empties more slowly, flattening the rise in glucose after eating and prolonging the sense of fullness. Central appetite circuits shift toward satiety, reducing the drive to eat between meals. Glucagon secretion is also suppressed when glucose is high. Many compounds target this receptor because native GLP-1 is degraded within minutes by dipeptidyl peptidase-4. Almost every design problem in the class is a half-life problem, and the answers differ. Some analogs attach a fatty-acid chain so the molecule binds albumin and circulates far longer. Others alter the amino acids around the cleavage site so the enzyme cannot act. These structural choices set how often a compound is given and how steeply blood levels rise and fall, which in turn shapes how much nausea a person experiences during the early adjustment period. The class also splits by how many receptors a molecule touches. Pure GLP-1 agonists engage this pathway alone. Dual and triple agonists add GIP, glucagon, or amylin activity on top of it, and combination products pair a GLP-1 agonist with a separate molecule. In every case the GLP-1 arm remains the backbone of the metabolic effect. Of all the pathways described on this site, this one has the strongest and most mature clinical footing. Several GLP-1 receptor agonists are approved medicines for type 2 diabetes, for obesity, or both, and the mechanism has been characterised in humans rather than inferred from animal work. That does not make every molecule in the class equivalent. Some listed here are still investigational, and their receptor activity being well understood says nothing about whether their particular formulation, purity, or long-term profile has been established.
Engaging the glucagon receptor to raise energy expenditure and mobilise liver fat.
Glucagon is the counter-regulatory partner to insulin, released from pancreatic alpha cells when blood glucose falls. Its receptor is a class B G-protein-coupled receptor concentrated in the liver, with additional expression in kidney, heart, and adipose tissue. Classical glucagon signalling raises blood glucose by driving glycogen breakdown and gluconeogenesis in the liver, which on its face makes it a strange thing to activate deliberately in someone with a metabolic disorder. The rationale rests on glucagon's other actions. Glucagon receptor signalling in the liver also promotes fatty-acid oxidation and reduces hepatic fat accumulation, and across the body it is associated with a rise in resting energy expenditure. In other words it increases the rate at which energy is burned rather than only the rate at which food is refused. Combining that with GLP-1 activity is intended to cancel the unwanted half of the effect: the GLP-1 arm suppresses appetite and improves glucose handling strongly enough to offset the glucose-raising tendency of the glucagon arm, leaving the energy expenditure and liver fat benefits behind. Compounds here take different routes to the same idea. Some are rationally designed multi-agonists built to hit a specific ratio across two or three receptors. Others are derived from oxyntomodulin, a naturally occurring gut hormone that already engages both the GLP-1 and glucagon receptors, and are then modified for stability and duration. The balance between the two arms is the central design variable, and it differs meaningfully between agents. A molecule weighted more heavily toward glucagon may do more for liver fat while demanding more careful attention to glucose. This is a less mature pathway than GLP-1 agonism. No glucagon-receptor-containing agent has the depth of approved-medicine history that pure GLP-1 agonists have, and several of the compounds listed here are still in clinical development rather than in general use. The underlying physiology of glucagon is well established, and the metabolic logic of combining it with an incretin is coherent, but the long-term consequences of chronically raising glucagon signalling in people, including effects on glucose control and cardiovascular parameters over years, are still being worked out. It is also worth noting that the amount of glucagon activity a molecule carries is a design choice made in the laboratory, not something a user can adjust, so comparisons between agents in this class are comparisons between fixed ratios rather than between adjustable ones.
The evidence
The core efficacy dataset for survodutide comes from a randomised, double-blind, placebo-controlled, dose-finding Phase 2 trial published in The Lancet Diabetes & Endocrinology (2024) and sponsored by Boehringer Ingelheim, in which 386 adults with obesity received survodutide (0.6-4.8 mg) or placebo over 46 weeks. Mean body-weight reductions were roughly -6.2%, -12.5%, -13.2% and -14.9% across ascending doses versus -2.8% for placebo under the treatment-policy analysis, with weight loss of nearly 19% among participants who reached and stayed on the highest dose. Weight loss was dose-dependent and had not clearly plateaued by week 46, suggesting further potential with longer treatment. The design limits interpretation: a single dose-finding study, placebo rather than active comparator, a 46 week horizon, and body weight as a surrogate rather than a clinical outcome. Survodutide has also been studied in a Phase 2 MASH trial, where it improved liver histology endpoints relative to placebo, and a later mediation analysis published in Hepatology examined how much of the liver benefit tracked with weight reduction and how much appeared independent of it. Larger Phase 3 obesity and MASH programs are underway to confirm efficacy and long-term safety; results reported so far include a Phase 3 trial of once-weekly survodutide in adults with obesity in the New England Journal of Medicine and the SYNCHRONIZE-MASLD Phase 3 trial in adults with obesity and metabolic dysfunction-associated steatotic liver disease in Nature Medicine. Several gaps remain explicit. There is no dedicated cardiovascular outcome trial result for survodutide, unlike semaglutide, which has published cardiovascular outcome data. There are no head-to-head randomised comparisons against semaglutide or tirzepatide, both of which have completed registrational programs and regulatory approval, so cross-trial percentage comparisons are not reliable. There is no multi-year durability, weight-regain, or paediatric evidence. As an investigational agent, its benefit-risk profile is not yet established.
The evidence, in brief
An investigational once-weekly glucagon/GLP-1 dual agonist from Boehringer Ingelheim and Zealand Pharma. A 386-participant randomized, placebo-controlled phase-2 obesity trial reported dose-dependent mean weight reductions reaching roughly 15% at 46 weeks versus about 3% for placebo, with gastrointestinal adverse events common during escalation. It is not approved anywhere; phase-3 obesity and MASH programs are still running.
- le Roux CW et al.: Glucagon and GLP-1 receptor dual agonist survodutide for obesity (phase 2)Lancet Diabetes Endocrinol, 2024 (PMID 38330987)
- PubMed search: survodutide obesityPubMed / NCBI
Evidence maturity
An evidence-only reading: approval status, human vs preclinical data, mechanism and safety. Popularity never raises it. Research file #061
Meaningful human evidence; not yet definitive.
Studied in human clinical trials; evidence is meaningful.
Claim receipts
Popular claims about Survodutide, checked against the state of the evidence. The verdict describes evidence maturity, never an invented study result.
Dose-dependent reductions versus placebo in a randomized placebo-controlled Phase 2 trial, with Phase 3 results now reported.
A Phase 2 MASH trial improved liver histology endpoints and Phase 3 work has reported, but it is not approved for that use.
It is investigational and has not been approved by the FDA, EMA or any other major regulator.
There are no head-to-head randomized comparisons, so cross-trial percentage comparisons are not reliable.
Gastrointestinal adverse events were common and far more frequent than placebo, especially during dose escalation.
Safety profile
In the Phase 2 obesity trial, adverse events were common and predominantly gastrointestinal, including nausea, vomiting and diarrhoea, occurring far more often than with placebo. These effects were most frequent during dose escalation, consistent with the GLP-1 drug class. A slower titration schedule was explored to improve tolerability. Beyond the trial data, the incretin class carries recognised issues that a regulator will expect to see characterised: gallbladder and biliary events, reported cases of pancreatitis, retained gastric contents relevant to sedation and anaesthesia, loss of lean mass alongside fat mass, and rodent thyroid C-cell findings that have shaped labelling for several agents. Glucagon receptor agonism adds its own questions, notably heart rate increases and hepatic parameters, which is why trials of this class typically require scheduled liver chemistry, heart rate and blood pressure monitoring, contraception and pregnancy exclusion, and structured stopping rules for intolerable gastrointestinal effects. Because survodutide is still in trials, rare or long-term risks remain incompletely characterized, and it should only be used under clinical-trial supervision. There is also a supply problem outside that setting: survodutide is not commercially manufactured for patients, so any material offered through grey-market research-chemical channels has no verified identity, potency, purity or sterility, no cold-chain guarantee, and no adverse-event reporting pathway. Contamination and mislabelling in that supply chain are documented concerns for peptides generally, and they compound the fact that the underlying molecule has no established safety profile in unsupervised use.
Compound notes
- Survodutide (BI 456906) is an investigational peptide that activates both the glucagon receptor and the GLP-1 receptor, engineered for a long half-life and weekly subcutaneous administration.
- GLP-1 activation slows gastric emptying, enhances glucose-dependent insulin secretion, and reduces appetite; glucagon-receptor activation is thought to add energy expenditure and hepatic fat mobilization.
- A Phase 2 dose-finding trial in 386 adults with obesity reported mean body-weight reductions up to roughly 15% over 46 weeks versus about 3% for placebo, with the curve not clearly plateaued by the end.
- It is co-developed by Boehringer Ingelheim and Zealand Pharma, and is also studied for MASH, where it holds an FDA Breakthrough Therapy designation.
Semaglutide targets GLP-1 only. Survodutide adds glucagon-receptor agonism, intended to raise energy expenditure and move liver fat as well as suppress appetite. Whether that translates into better outcomes is still being measured.
- Investigational; not approved by the FDA, EMA, or any major regulator, and appropriate only within a registered clinical trial.
- Adverse events in trials were predominantly gastrointestinal (nausea, vomiting, diarrhea) and most frequent during escalation, consistent with the GLP-1 class.
- Rare and long-term risks remain incompletely characterized.
Regulatory status
Survodutide is an investigational drug and has not been approved by the FDA, EMA, or any major regulator for any indication. It carries an FDA Breakthrough Therapy designation for MASH with fibrosis. Any use outside a registered clinical trial is unapproved.
Investigational, currently in registered human clinical trials.
By the numbers
- 01Dual GLP-1 receptor and glucagon receptor agonist
- 02Once-weekly subcutaneous injection (investigational)
- 03Co-developed by Boehringer Ingelheim and Zealand Pharma
- 04Phase 2 obesity trial showed up to ~15% mean weight loss over 46 weeks
- 05Also studied for MASH with FDA Breakthrough Therapy designation
- 06Not FDA/EMA approved; available only in clinical trials
Survodutide: research formats
Choose the format you are researching to see route-specific notes.
Once-weekly subcutaneous injection inside registered clinical trials. Not an approved medicine.
Survodutide is an investigational dual GLP-1 and glucagon receptor agonist engineered for a long half-life so it can be given once weekly by subcutaneous injection. It is available only within regulated clinical trials, so there is no marketed presentation, no pen device on the market, and no FDA-labeled titration schedule to reproduce here.
In the Phase 2 obesity trial, adverse events were predominantly gastrointestinal and were most frequent during dose escalation, which is why the sponsors explored a slower titration. Escalation pacing in this class is a protocol decision made by investigators, not a self-managed one.
Survodutide carries an FDA Breakthrough Therapy designation for MASH with fibrosis, which is a development-pathway status and not an approval. Use outside a registered trial is unapproved.
Sources
Every factual claim above resolves to a real, published source.
- Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trialle Roux et al., Lancet Diabetes Endocrinol, 2024 · PMID 38330987
- Survodutide obesity and MASH clinical trials (PubMed search)PubMed search results
- Survodutide Once Weekly for the Treatment of Adults with ObesityN Engl J Med, 2026 · PMID 42253238
- Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trialNat Med, 2026 · PMID 42252333
- Weight reduction-dependent/-independent effects of survodutide on liver endpoints: Mediation analysis of a phase 2 trial in MASHHepatology, 2026 · PMID 42545725
- Registered survodutide clinical trials (ClinicalTrials.gov search)ClinicalTrials.gov registry search
Cite this page
PepCue. “Survodutide: the evidence.” PepCue, reviewed June 1, 2026. https://www.pepcue.app/p/survodutide.
Log your doses, run the vial math, and keep a provider-ready record in PepCue.